Abstract:Background: Allergic drug reaction or drug allergy is an immunologically mediated drug hypersensitivity reaction (DHR). G-protein coupled receptors (GPCRs) are common drug targets and communicate extracellular signals that initiate cellular responses. Recent evidence shows that GPCR MRGPRX2 is of major importance in IgE-independent pseudo-allergic DHRs based on the suspected interactions between many FDA-approved peptidergic compounds and MRGPRX2. Objective: Our aim was to uncover novel MRGPRX2-selective and -potent agonists as drug candidates responsible for clinical features of pseudo-allergic DHRs. Methods: We conducted a primary high-throughput screening (HTS), coupled with mutagenesis targeting the MRGPRX2 N62S mutation, on a panel of 3,456 library compounds. We discovered pharmacologically active hit compounds as agonists of the MRGPRX2 protein according to high degrees of potency evaluated by the calcium response and validated by the degranulation assay. Using the molecular tool Forge, we also characterized the structure-activity relationship shared by identified hit compounds. Results: The alternative allele of single nucleotide polymorphism rs10833049 (N62S) in MRGPRX2 demonstrated loss-of-function property in response to substance P and antineoplastic agent daunorubicin hydrochloride. We applied a unique assay system targeting the N62S mutation to the HTS and identified 84 MRGPRX2-selective active hit compounds representing diverse classes according to primary drug indications. The top five highly represented groups included fluoroquinolone and non-fluoroquinolone antibiotics; antidepressive/antipsychotic; antihistaminic and antineoplastic agents. We classified hit compounds into 14 clusters representing a variety of chemical and drug classes beyond those reported, such as opioids, neuromuscular blocking agents, and fluoroquinolones. We further demonstrated MRGPRX2-dependent degranulation in the human mast cell line LAD2 cells induced by three novel agonists representing the non-fluoroquinolone antibiotics (bacitracin A), anti-allergic agents (brompheniramine maleate) and tyrosine-kinase inhibitors (imatinib mesylate). Conclusion: Our findings could facilitate the development of interventions for personalized prevention and treatment of DHRs, as well as future pharmacogenetic investigations of MRGPRX2 in relevant disease cohorts.

A Paper-Based ELISA for Rapid Sensitive Determination of Anaphylaxis-Related MRGPRX2 in Human Peripheral Blood

A Novel ELISA Method to Determine Human MrgX2 in Chronic Urticaria

A Novel Human MrgX2-ELISA Kit to Detect MrgX2 Concentration Associated with Chronic Urticaria

Serum MRGPRX2 as a Long-term Biomarker for Iodinated Contrast Media-Induced Anaphylaxis

Establishment of Substance P Modified Affinity Chromatography for Specific Detection and Enrichment of Mas-related G Protein–coupled Receptor X2

Liquid Chromatography Tandem Mass Spectrometry Based Label-Free Quantification Method for Assessment of Allergen-Induced Anaphylactoid Reactions.

Paper-based microfluidics and tailored gold nanoparticles for visual colorimetric detection of multiplex allergens

MrgX2-SNAP-tag/cell Membrane Chromatography Model Coupled with Liquid Chromatography-Mass Spectrometry for Anti-Pseudo-allergic Compound Screening in Arnebiae Radix.

Point-of-care personalized rapid diagnosis of allergies using peptide epitopes and SPR multiplexed detection

A novel MRGPRX2-targeting antagonistic DNA aptamer inhibits histamine release and prevents mast cell-mediated anaphylaxis

Anti-allergic Drug Screening in Single Living Mast Cells by Means of a Novel Surface Plasmon Resonance Imaging System

Development of an Environmentally Sensitive Fluorescent Peptide Probe for MrgX2 and Application in Ligand Screening of Peptide Antibiotics.

The Human Mast Cell Line-1 Cell Membrane Chromatography Coupled with HPLC-ESI-MS/MS Method for Screening Potentical Anaphylactic Components from Chuanxinlian Injection.

Biological screening of a unique drug library targeting MRGPRX2

Microfluidic system for high-throughput immunoglobulin-E analysis from clinical serum samples

Simultaneous Identification of the Anaphylactoid Components from Traditional Chinese Medicine Injections Using Rat Basophilic Leukemia 2H3 and Laboratory of Allergic Disease 2 Dual-Mixed/cell Membrane Chromatography Model

A rapid ELISA platform with no sample preparation requirement

Ultrasensitive Multi-Analyte Electrochemical Immunoassay Based On Gnr-Modified Heated Screen-Printed Carbon Electrodes And Ps@Pda-Metal Labels For Rapid Detection Of Mmp-9 And Il-6

Novel small molecule MRGPRX2 antagonists inhibit a murine model of allergic reaction

Rapid Screening of Monoclonal Antibodies Against Porcine Circovirus Type 2 Using Colloidal Gold-Based Paper Test.

Accurate Quantification of Β-Hexosaminidase Released from Laboratory of Allergic Diseases 2 Cells Via Liquid Chromatography Tandem Mass Spectrometry Method.